PCR diagnosis in gynecology
Last reviewed: 19.11.2021
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
With the help of the method of polymerase chain reactions (PCR), it is now possible to identify a variety of infectious agents located in the focus of inflammation. The most modern of the molecular methods of DNA hybridization makes it possible to identify the human papillomavirus by serotypes. Molecular studies currently allow the determination in the serum of blood of so-called oncomarkers - abnormal antigens affected by malignant cell changes. With their help, cancer is recognized at the earliest stages (with the help of the antigen-antibody reaction), when treatment is most effective.
Types of oncomarkers used in gynecological practice
|
Oncomarkers
|
Detected diseases
|
| Cancer embryonic antigen (CEA) | Monitoring of cancer of the rectum, stomach, breast, bronchi |
| alpha-fetoprotein | Monitoring of pregnancy, diagnosis and monitoring of primary hepatocellular cancer and embryonic-cell tumors |
| CA 15-3 | Monitoring of breast cancer therapy (used in combination with CEA) |
| CA 125, CA 19-9 | Monitoring of ovarian cancer |
| CA 72-4 | Stomach cancer, mucinous ovarian cancer |
| Human chorionic gonadotropin (beta-HCG) | Neseminomnye embryonic-cellular tumors, chorionic epithelioma, bladder drift |
| Mucin-like antigen | Mammary cancer |